Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FTC Chairman-Designate Muris Supports Synergies As Merger Justification

Executive Summary

The Bush Administration's nominee for Federal Trade Commission chairman, George Mason University law professor Timothy Muris, is likely to push for the antitrust enforcement agency to give more weight to efficiencies as a justification for mergers.

You may also be interested in...



AmerisourceBergen Merger Complete, FTC Says Efficiencies Justify Approval

Federal Trade Commission approval of the merger of AmeriSource and Bergen Brunswig reflects the agency's conclusion that the combined firm will be able to expand its services more rapidly than either company on its own.

Generic Reform Advocates See Reimport Bill As Model: Is Hatch Obstacle?

Waxman/Hatch reform legislation could move in the 107th Congress in a fashion similar to the reimportation bill enacted in 2000, Generic Pharmaceutical Association President William Nixon suggested during the Schwab Washington Research Group healthcare conference in Washington, D.C. May 9.

Generic Reform Advocates See Reimport Bill As Model: Is Hatch Obstacle?

Waxman/Hatch reform legislation could move in the 107th Congress in a fashion similar to the reimportation bill enacted in 2000, Generic Pharmaceutical Association President William Nixon suggested during the Schwab Washington Research Group healthcare conference in Washington, D.C. May 9.

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

PS037548

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel